Coronavirus - SARS-CoV-2: Risk group and biosafety consensus for laboratory with infectious samples

• Autor(a) principal: Binsfeld, Pedro Canisio
• Data de Publicação: 2020
• Outros Autores: Colonello, Nínive Aguiar
• Tipo de documento: preprint
• Idioma: por
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/399
• topic: Biossegurança; COVID-19; Coronavírus; laboratório de diagnóstico; Biosafety; COVID-19; Coronavirus; diagnostic laboratory

The pandemic outbreak of coronavirus 2 (SARS-CoV-2), which began in China, is still ongoing in Brazil and worldwide, with over than 4.0 million confirmed cases and 280,000 deaths after 4 months of the virus spreading. It is now the top-priority pathogen to be dealt with due to its high transmissibility, severe illness and associated mortality, absence of effective prophylactic and therapeutic measures with knowledge gaps in human epidemiology, immunity and pathogenesis. To meet the increasing demand of the diagnostic and clinical services, it is necessary to improve biosafety and expand laboratory capabilities since the existing laboratories and workers cannot meet the emerging demand. This article highlights the risk class and biosafety consensus of the minimum requirements for the SARS-COV-2 clinical and diagnostic laboratories, as well as, the prevention of the biorisk to the workers, avoiding accidental dissemination to their families and the community.